Clinical features and outcomes of head and neck castleman disease.

@article{Chen2012ClinicalFA,
  title={Clinical features and outcomes of head and neck castleman disease.},
  author={Yan-feng Chen and Weidong Zhang and Chuan-zheng Sun and Dian Ouyang and Wen-kuan Chen and Rong-zhen Luo and Ming-wei Wu},
  journal={Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons},
  year={2012},
  volume={70 10},
  pages={2466-79}
}
PURPOSE To increase the understanding of head and neck Castleman disease (CD) and to improve its diagnosis and management. PATIENTS AND METHODS A retrospective study was performed on the medical records of 14 patients with cervical CD treated at the Sun Yat-sen University Cancer Center from January 2000 through December 2009. The predictor variables were age, gender, site, size, and treatment modality. The outcome variables were survival time and recurrence. RESULTS Neck level II (9/14) was… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2010

Similar Papers

Loading similar papers…